IMI markets a family of surgical probes including Surgical Gamma Probes for sentinel lymph node biopsy in breast cancer and melanoma surgery, and PET Probes for intraoperative Gamma Probe and Beta Probe tumor detection and surgical margin evaluation.
Our technology is based on the injection of radiopharmaceuticals that emit gamma or beta rays. Surgeons use our probes to locate the sentinel lymph nodes or cancerous tissues that accumulate the radiopharmaceuticals.